Publication of List of Manufacturers Suspended from Licensing for the Manufacture of Therapeutic Goods – 9 April 2024

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring these products are safe and of high quality. This Act addresses the problem of inadequate oversight and regulation of the manufacture of therapeutic goods, aiming to protect public health by preventing the distribution of unsafe or substandard products. Enacted by the Parliament of Australia, the policy objective of the Act is to maintain and improve the health of Australians by regulating therapeutic goods and ensuring their quality, safety, and efficacy. The Therapeutic Goods Administration, under the auspices of the Department of Health and Aged Care, administers this Act and is responsible for the enforcement of its provisions, including the suspension of manufacturing licenses when necessary to protect public health. This legislative framework allows for stringent controls over the therapeutic goods market, ensuring compliance and accountability from manufacturers. The 2024 publication by Katherine Clark, acting as the Delegate of the Secretary of the Department of Health and Aged Care, pertains to the suspension of manufacturing licenses for specific companies as per the Therapeutic Goods Act 1989. This action underscores the importance of regulatory oversight in maintaining the integrity of the therapeutic goods market. By suspending the licenses of EDWARD D CO PTY LTD T/A NATIONAL PHARMA PACK and AEGROS LIMITED, the Administration is taking proactive steps to address potential risks to public health. The suspensions are effective for specified periods, demonstrating the Administration's commitment to ensuring that therapeutic goods meet stringent quality and safety standards. This measure reflects the ongoing efforts to enforce the Act's provisions and uphold the health and safety of the Australian public.

Scope and Application

The Therapeutic Goods Act 1989 applies to manufacturers of therapeutic goods within Australia, establishing a regulatory framework to ensure that these products are of acceptable quality and safety. The Act governs both natural and synthetic products intended for use in the diagnosis, treatment, mitigation, or prevention of a disease, ailment, defect, or injury in humans or animals. This legislation is enforced by the Therapeutic Goods Administration (TGA), which operates under the Department of Health and Aged Care. The Act applies to entities such as companies and individuals who manufacture therapeutic goods, including pharmaceuticals, medical devices, and blood products, and it covers all states and territories within Australia. The geographic reach of the Act is national, as it applies uniformly across the Commonwealth. The Act includes provisions that allow for the suspension of manufacturing licences under certain conditions, as illustrated by the recent publication regarding the suspension of licences for EDWARD D CO PTY LTD T/A NATIONAL PHARMA PACK and AEGROS LIMITED. This reflects the regulatory authority's power to enforce compliance through administrative measures. There are no specific exclusions or exemptions mentioned in the provided excerpt, but the Act typically includes provisions for exclusions based on certain criteria such as the type and scale of manufacturing operation, which may be further detailed in subordinate instruments or guidelines issued by the TGA.

Key Provisions

The Therapeutic Goods Act 1989, under Section 41, allows the Secretary to suspend a manufacturer’s licence for therapeutic goods, as evidenced by the publication of suspended licences for Edward D Co Pty Ltd T/A National Pharma Pack and AEGROS Limited. This suspension is a regulatory measure that restricts the entities' ability to manufacture therapeutic goods, which are products like medicines, medical devices, and blood products that are used to treat, diagnose, cure, or prevent diseases or conditions in humans. The licence suspension for Edward D Co Pty Ltd, licence number MI-2009-LI-06243-3, took effect on 22 March 2024 and will last until 22 March 2025, while the suspension for AEGROS Limited, licence number MI-19042005-LI-000513-1, was effective from 26 March 2024 to 26 August 2024. These suspensions impose specific obligations on the entities concerned, primarily prohibiting them from manufacturing therapeutic goods during the period of suspension. The entities must comply with the terms of the suspension by halting any manufacturing activities related to therapeutic goods. This includes ceasing production, distribution, and any related activities that fall under the scope of the suspended licence. The entities are also required to notify any relevant stakeholders of the suspension and to provide evidence of compliance with the suspension order as requested by the Therapeutic Goods Administration (TGA). Failure to comply with the terms of a licence suspension under the Therapeutic Goods Act 1989 can result in significant legal consequences. Offences under this Act may include continuing to manufacture therapeutic goods during a suspension period, which is considered a breach of the regulatory requirements. The Act provides for both civil and criminal penalties for non-compliance. For instance, individuals or entities found to be in breach of a suspension order may face fines of up to $1,650,000 for a corporation, and imprisonment for up to five years if the offence is of a serious nature. Additionally, the TGA may take further enforcement actions, such as revoking the licence or pursuing legal action to ensure compliance with the Act’s provisions.